BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion
BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could ...
BioMarin的PALYNZIQ在青少年PKU治疗中显示出良好前景
BioMarin是一家成立于1997年的生物技术公司，专注于为基因定义疾病开发治疗方法。该公司宣布PEGASUS试验结果是向可能为年轻PKU患者提供新治疗选择迈出的重要一步。凭借 InvestingPro ...
BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent ...
BioMarin's Phase 3 trial shows Palynziq significantly reduces blood Phe in adolescents with PKU. The company plans a ...
Zacks.com on MSN2 天
BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study
Based on the late-stage data, BioMarin plans to submit a regulatory filing for expanding the label of its PKU drug Palynziq in adolescents before this year's end.
Pharmabiz2 天
BioMarin Pharma’s phase 3 PEGASUS trial evaluating Palynziq in adolescents with ...
San Rafael, California Thursday, April 3, 2025, 18:00 Hrs [IST] ...
The Pharma Letter2 天
Positive pivotal data for Palynziq in adolescents
US biotech BioMarin Pharmaceutical (Nasdaq: BMRN) yesterday revealed that the Phase III PEGASUS trial evaluating Palynziq (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a ...
BioMarin: Phase 3 PEGASUS trial of Palynziq met primary endpoint
Pharmaceutical announced that the Phase 3 PEGASUS trial evaluating Palynziq met its primary efficacy endpoint, demonstrating a ...
Yahoo Finance3 天
BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent ...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released topline data from the Phase 3 PEGASUS trial evaluating Palynziq (pegvaliase-pqpz) compared to diet alone in 55 adolescents aged 12-17 with ...
Medindia3 天
BioMarin Announces Positive Pivotal Data for PALYNZIQ (pegvaliase-pqpz) in Adolescents with ...
PR Newswire SAN RAFAEL, Calif., April 2, 2025 Company plans to submit for regulatory approval later this year SAN RAFAEL, Calif., April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceut ...